(IN BRIEF) The Institute of Cancer Research has welcomed NICE’s recommendation of talazoparib in combination with enzalutamide for adults with metastatic prostate cancer, providing a new treatment option for around 2,400 patients in England who are unsuitable for chemotherapy. Backed … Read the full press release →
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged BRCA mutations, DNA repair gene mutations, enzalutamide, Institute of Cancer Research London, metastatic prostate cancer, NICE recommendation, NICE Recommendation of Talazoparib Marks New Treatment Option for Advanced Prostate Cancer, PARP inhibitors, prostate cancer treatment, Royal Marsden NHS Foundation Trust, TALAPRO trials, talazoparib, Talzenna, targeted cancer therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
